Abstract
Diabetes mellitus is an epidemic disease, and by 2025, the number of diabetic individuals could reach 300 million worldwide. Given the importance of this disease, new drugs have been developed to control blood glucose levels. Among them, there are agonists of the glucagon-likepeptide1 (GLP-1) and inhibitors of dipeptidyl peptidase-4 (DPP-4). It was discovered, however, that such drugs hav…